Skip to main content

Table 2 Vaccination schedule

From: Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial

Arm Administration 1 (day 0) Administration 2 (day 21)
1 500 μg FLU-v in 0.5 ml salinea (suspension) 500 μg FLU-v in 0.5 ml salinea (suspension)
2 500 μg FLU-v in 0.25 ml WFI and 0.25 ml Montanide ISA-51 (emulsion) 0.5 ml saline (solution)
3 0.5 ml saline (solution) 0.5 ml saline (solution)
4 0.25 ml WFI and 0.25 ml Montanide ISA-51(emulsion) 0.5 ml saline (solution)
  1. aMade by mixing 0.25 ml of 0.01 M HCl and 0.25 ml 0.01 sM NaOH